I need to know
- FDA Green Marketing for the first blood test that helps to diagnose Alzheimer’s disease
- The test measures the two proteins of beta-amyloid and P-TAU217.
- Experts believe that this will increase access to Alzheimer’s detection and reduce the dependence on expensive PET scans and invasive spinal tabs.
The Food and Drug Administration granted marketing permission to the first blood test, which helps to diagnose Alzheimer’s disease.
May 16, agency presentation Test permission-Lumipulse G ptau217/ß-amilloid 1-42 plasma ratio-Pennsylvania-based biotechnology firm fujirebio diagnosis. Tests work by measuring protein beta-amyloid and P-TAU217, which are considered to be the characteristics of Alzheimer’s disease.
Alzheimer is A Degenerative brain disease It is caused by complex brain changes after cell damage. It gradually affects memories, thoughts and actions as much as it interferes with everyday tasks.
Blood tests have been pioneered to use for people over 55 years old, representing the signs and symptoms of the disease. The FDA says this new test can help to increase access to Alzheimer’s disease detection and to reduce the dependence on PET scan or spinal tabs.
People are here! How quickly can I solve it? Play now!
Getty image
Do not miss the story-people’s free daily newsletters can keep the latest information on what people offer from a famous news to a powerful human interest.
Dr. Michelle Tarver, the director of devices and radiation health centers, said, “Nearly 7 million Americans live as Alzheimer’s disease and this figure is expected to increase to almost 13 million people.” Today’s room is an important stage of diagnosis of Alzheimer’s disease, which is easier and potentially accessible to American patients at the beginning of the disease.
The FDA said that 499 plasma samples were evaluated from patients with cognitive impairment and compared with the results of the PET scan or spinal tab and blood test results.
The researchers found that blood tests are accurate in identifying PET scan or spinal tabs in detecting Alzheimer’s patients, and the exact 97%of them are accurate to identify patients without diseases.
Dr. Richard Isaacson, a specialist in the prevention neurology who founded one of the first Alzheimer’s preventive clinics, said. CNN He has been using this blood test for many years for research and has applauded the FDA clearance.
“You can provide more clearly whether a person who suffers from memory can have a bottle of Alzheimer’s. This test can perform a screening test.” “This is a much simpler screening test with reasonable accuracy. A person who has a cognitive decrease in a doctor says that there is actually a symptom of Alzheimer’s disease.”
Clearance emphasizes that more research is needed to go forward, while ISAACSON is needed to determine how to interpret blood test results and how to make medical decisions.
